Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lipoic acid, also known as alpha-lipoic acid (ALA), has been investigated for its potential role in supporting or treating diabetic retinopathy due to its antioxidant properties. Diabetic retinopathy is characterized by oxidative stress and inflammation in retinal tissues, which contribute to vascular damage and vision loss. ALA is a potent antioxidant capable of regenerating other antioxidants, scavenging free radicals, and improving endothelial function.

Animal studies have demonstrated that ALA supplementation can reduce retinal oxidative stress, inhibit the formation of advanced glycation end-products (AGEs), and decrease inflammatory markers in diabetic models. For example, some rodent studies have shown reduced vascular leakage and improved retinal structure with ALA administration. Human studies, however, are limited. A few small clinical trials suggest that ALA may modestly improve visual function or slow progression of early-stage diabetic retinopathy, but the sample sizes are small and study designs vary.

Systematic reviews and meta-analyses generally conclude that while ALA is promising as an adjunct therapy due to its biological plausibility and preclinical data, robust clinical evidence is lacking. Large, well-controlled trials are needed to establish its efficacy and safety in patients with diabetic retinopathy. Thus, while there is a scientific rationale and some preliminary evidence, the overall level of clinical support is moderate to low.

More about Lipoic Acid
More about Diabetic Retinopathy

Other ingredients used for Diabetic Retinopathy

Other health conditions supported by Lipoic Acid

Products containing Lipoic Acid